Remember that this is an approval to be sold, not a contract to
actually sell anything - more of a regulatory thing than anything
else. They still have to convince the individual labs that they
actually want the products being sold, and doing so could be a
challenge. It is highly likely that there are a number of other
companies with similar products that already have approval.

A decade ago Nanogen was one of very few companies with an SNP
detection system, but now there are a great number of these sorts of
systems, and newer methods as well. Direct sequencing is now good
enough in some cases as well. Microfluidics and chip-based systems are
used everywhere. The products were great in 1993, but it took an
absurdly long time to bring them to market, and they aren't too
exciting now.

Of course, this is still good news, and it is nice to see Nanogen
starting to do things again, after years of doing nothing. Perhaps
they will become relevant again, which would be very nice to see. But
this isn't 2000, and getting a GSA approval isn't going to cause the
stock price to jump tenfold.

I should also comment that I consider the absurd claims of the other
poster here (the whale one) to be quite absurdly sensationalist and
completely flawed. The technology is good, but it isn't going to
change the world. In many cases this sort of diagnostic system is
already being used. It doesn't help *that* much.